A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
November 7, 2023
Primary Completion Date
January 22, 2024
Study Completion Date
January 22, 2024
Conditions
Healthy
Interventions
DRUG
Digoxin
Oral administration
DRUG
Nemtabrutinib
Oral administration
Trial Locations (1)
66219
ICON (Site 0001), Lenexa
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT06625827 - A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012) | Biotech Hunter | Biotech Hunter